Ras-related C3 botulinum toxin substrate 1 (RAC1) regulates glucose-stimulated insulin secretion via modulation of F-actin by unknown
ARTICLE
Ras-related C3 botulinum toxin substrate 1 (RAC1) regulates
glucose-stimulated insulin secretion via modulation of F-actin
S. Asahara & Y. Shibutani & K. Teruyama & H. Y. Inoue & Y. Kawada & H. Etoh &
T. Matsuda & M. Kimura-Koyanagi & N. Hashimoto & M. Sakahara & W. Fujimoto &
H. Takahashi & S. Ueda & T. Hosooka & T. Satoh & H. Inoue & M. Matsumoto &
A. Aiba & M. Kasuga & Y. Kido
Received: 20 July 2012 /Accepted: 17 January 2013 /Published online: 15 February 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis The small G-protein ras-related C3 botuli-
num toxin substrate 1 (RAC1) plays various roles in mamma-
lian cells, such as in the regulation of cytoskeletal organisation,
cell adhesion, migration and morphological changes. The pres-
ent study examines the effects of RAC1 ablation on pancreatic
beta cell function.
Methods Isolated islets from pancreatic beta cell-specific
Rac1-knockout (betaRac1−/−) mice and RAC1 knockdown
INS-1 insulinoma cells treated with small interfering RNA
were used to investigate insulin secretion and cytoskeletal
organisation in pancreatic beta cells.
Results BetaRac1−/− mice showed decreased glucose-
stimulated insulin secretion, while there were no apparent
differences in islet morphology. Isolated islets from the mice
had blunted insulin secretion in response to high glucose levels.
In RAC1 knockdown INS-1 cells, insulin secretion was also
decreased in response to high glucose levels, consistent with
the phenotype of betaRac1−/− mice. Even under high glucose
levels, RAC1 knockdown INS-1 cells remained intact with
F-actin, which inhibits the recruitment of the insulin granules,
resulting in an inhibition of insulin secretion.
Conclusions/interpretation In RAC1-deficient pancreatic
beta cells, F-actin acts as a barrier for insulin granules and
reduces glucose-stimulated insulin secretion.
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Introduction
Type 2 diabetes mellitus is known to be caused by periph-
eral insulin resistance and pancreatic beta cell failure, and a
number of important findings have been made for the mo-
lecular mechanism of impaired insulin secretion. The cyto-
skeleton and cell adhesion of pancreatic beta cells are
reported to be involved in insulin secretion, and low-
molecular-weight G proteins also play a major role in insu-
lin secretion. About 40 years ago, an electron microscopy
study showed that F-actin functions as a barrier for insulin
granules [1]. This was the first report to show a relation
between the beta cell cytoskeleton and insulin secretion.
Recent studies have found that adjacent beta cells influ-
ence each other’s insulin secretion by modulating the F-
actin barrier through ephrin receptor (Eph)–ephrin signal-
ling [2]. Such findings suggest that the molecules that reg-
ulate the cytoskeleton are important for insulin secretion. In
addition, cell culture experiments have also revealed that the
amount of insulin secretion is reduced when there is a decrease
in the production of cell division cycle 42 (CDC42), which is a
low-molecular-weight G protein [3]. Furthermore, RAB27A,
member RAS oncogene family (RAB27A) has been shown to
play an important role in the docking of insulin granules to the
cell membrane [4]. The various roles of small G proteins,
including the above examples, in pancreatic beta cells have
been well described [5]. In this study, we examined the G-
protein ras-related C3 botulinum toxin substrate 1 (RAC1),
which plays major roles in various phenomena in the cyto-
skeleton, in oxidative stress and in secretion. Because of its
diverse functions, RAC1 sometimes plays both positive and
negative roles in pancreatic beta cells [6]. Previous studies
using dominant-negative mutations have shown that inhibit-
ing the functions of RAC1 in cultured beta cells results in
decreased insulin secretion [7, 8], suggesting that RAC1 could
be an important molecule for insulin secretion; however,
no in vivo analyses or studies of the mechanism have been
reported to date, and the role of RAC1 at the individual
level remains unclear. Here, we conducted a functional
analysis of RAC1 in beta cells, using genetically modified
mice and cultured cell lines.
Methods
Mice We generated heterozygous pancreatic beta cell-
specific Rac1-knockout (betaRac1−/−) mice by crossing
Rac1flox/flox mice, which harbour a modified endogenous
Rac1 gene in which exon1 is flanked by loxP sites [9], with
those that express the Cre recombinase gene under the
control of the rat insulin-2 gene [10], as described previous-
ly. The mice were backcrossed to mouse strain C57BL/6J
for at least eight generations. C57BL/6J mice were obtained
from Clea Japan (Tokyo, Japan). Animals were maintained
on a 12 h light, 12 h dark cycle and fed normal chow or a
high-fat diet containing 30% (wt/wt) fat (14% bovine fat,
14% porcine fat and 2% soybean oil) [11] from the time of
weaning (3 weeks old). Blood glucose and plasma insulin
concentrations were determined as described previously [12,
13]. All experiments were performed with male mice. This
study was performed in accordance with the guidelines of
the Animal Ethics Committee of Kobe University Graduate
School of Medicine.
OGTT Mice were deprived of food for 16 h. Blood was
collected immediately before and 15, 30, 60 and 120 min
after the oral administration of glucose (1.5 mg/g) [14].
Cell culture and transfection of small interfering RNA At
24 h before transfection, INS-1 cells were re-plated in 12-
well plates (60 mm dishes) and transfected with small inter-
fering (si)RNA for Rac1 (SMARTpool; Dharmacon, Lafay-
ette, CO, USA) or scramble controls (Non-Targeting
siRNA#2; Dharmacon) with DharmaFECT2 transfection
reagent (Dharmacon). After further incubation for 48 h for
mRNA, or for 72 h for protein, the cells were harvested for
evaluation of insulin secretion and mRNA expression or
protein levels.
Assay of insulin secretion from isolated islets Islets were
isolated from 8-week-old mice as described [13, 15]. To
assay insulin release, five islets were manually selected,
incubated in Krebs–Ringer solution, and stimulated at 37°C
for 30 min with various concentrations of glucose, KCl or
tolbutamide. The islets were then collected by centrifugation
and the supernatant fraction was assayed for insulin secretion
using an ELISA kit with a mouse standard (Shibayagi,
Gunma, Japan). To measure islet insulin content, islets were
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solubilised in acid-ethanol solution (74% ethanol, 1.4% HCl
[vol./vol.]) overnight at 4°C before insulin ELISA. Insulin
secretion from INS-1 cells was measured after a 30 min incu-
bation in Krebs–Ringer–bicarbonate–HEPES buffer (KRBH;
140 mmol/l NaCl, 3.6 mmol/l KCl, 0.5 mmol/l NaH2PO4,
0.5 mmol/l MgSO4, 1.5 mmol/l CaCl2, 2 mmol/l NaHCO3,
10 mmol/l HEPES and 0.1% BSA; pH 7.4) containing the
indicated stimulators. The insulin content was determined
after extraction with acid ethanol.
Real-time RT-PCR analysis Total cellular RNAwas extracted
from INS-1 cells with an RNeasy kit (QIAGEN, Valencia, CA,
USA). Real-time RT-PCR analysis of the total RNA extracted
from controls and RAC1-knockdown INS-1 cells was per-
formed as described [16]. For real-time quantitative reverse
transcription and PCR analysis, cDNA synthesised from total
RNA was evaluated in a sequence detector (model 7900;
Applied Biosystems, Foster City, CA, USA) with specific
primers (electronic supplementary material [ESM] Table 1)
and SYBR Green PCR Master Mix (Applied Biosystems).
The relative abundance of mRNAs was calculated with cyclo-
philin mRNA as the invariant control.
Immunoblot analysis We prepared lysates of isolated islets
or INS-1 cells as described previously [12, 13]. The lysates
were probed with antibodies to RAC1 (BD Biosciences
Pharmingen, San Diego, CA, USA), pan-actin (Cell Signal-
ing, Danvers, MA, USA), and β-actin (Sigma-Aldrich, St
Louis, MO, USA).
Immunostaining and morphometric analysis The pancreas
was immersed in Bouin’s solution, embedded in paraffin and
sectioned at 4–5 μm thickness. Sections were stained with
antibodies to insulin, glucagon (Dako, Glostrup, Denmark),
and RAC1 (BD Biosciences). Immune complexes were
detected with secondary antibodies conjugated with either
cyanine 3 or FITC (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA). Quantification of beta cell mass was
conducted as described [12, 13].
F-actin staining analysis F-actin was stained using an F-
actin Visualization Biochem Kit (Cytoskeleton, Denver, CO,
USA). INS-1 cells cultured on a 12×12 mm cover slip were
fixed by fixative solution and incubated for 10 min. After
washing the cover slip, INS-1 cells were permeabilised by
permeabilisation buffer (pH 7.0) and incubated for 5 min.
After washing, the F-actin of INS-1 cells was stained with
rhodamine phalloidin and incubated for 30 min. For RAC1
staining, an anti-RAC1 antibody (BD Biosciences) was used.
Assay of F-actin/G-actin in vitro We assayed F-actin/G-actin
in INS-1 cells with the G-actin/ F-actin In vivo Assay Kit
(Cytoskeleton, Denver, CO, USA). We scraped INS-1 cells in
LAS2 buffer (pH 6.9) and lysed them to disrupt the cell
membrane. After centrifuging the lysate to a pellet of unbro-
ken cells, we centrifuged the supernatant fraction at 100,000 g
to separate F-actin from soluble G-actin. We analysed the
supernatant fraction for actin content by immunoblotting with
anti-actin antibody.
Perfusion analysis Perfusion studies of mouse pancreases
were performed as described previously [17]. Briefly,
overnight-fasted (16 h) male mice (10–12 weeks old) were
used. The perfusion protocol began with a 10 min equilibra-
tion period using KRBH buffer. The flow rate was 1 ml/min.
Total internal reflection fluorescence microscopy analysis
Mouse pancreatic islets were isolated by the collagenase
digestion method and dispersed in Ca2+- and Mg2+-free
PBS containing 0.016% trypsin and 0.0066% EDTA at
37°C for 5 min. After washing with ice-cold KRBH, the
cells were transferred onto a glass cover slip with high
refractive index (refractive index, n 1.8 at 488 nm) (Olym-
pus, Tokyo, Japan) coated with 10 μg/cm2 laminin (Sigma)
at 37°C for 3 h. The cells were then infected with adenovirus
carrying insulin-Venus at a multiplicity of infection of ten
and cultured in DMEM or RPMI-1640 medium supple-
mented with 10% fetal bovine serum under a humidified
condition of 95% air and 5% CO2. After culturing infected
primary beta cells for 48 h, the cells on the glass cover slips
were pre-incubated on the thermostat-controlled stage at 37°C
in KRBH containing 2.8 mmol/l glucose. Then, 30 min after
pre-incubation, the cells were incubated with 16.8 mmol/l
glucose for 15 min, fixed, immunostained with anti-insulin
antibody, and observed by total internal reflection fluores-
cence microscopy (TIRFM) as described [18, 19].
Statistical analysis Data are presented as means ± SEM
values and compared by ANOVA. A p value of <0.05 was
considered significant.
Results
Generation of pancreatic beta cell-specific Rac1-knockout
mice Generalised deficiency of RAC1 in mice has already
been reported to be embryonically lethal [20]. Therefore, we
generated Rac1-floxed mice with a floxed allele in which
exon 1 of Rac1 was sandwiched by loxP [9]. The Rac1-
floxed mice were crossbred with Ins-Cre mice that express
beta cell-specificCre, and consequentlyRac1flox/flox, Ins-Cre/+
mice (betaRac1−/−) deficient in beta cell-specific RAC1 were
created, as were Rac1flox/flox control mice. A western blot
confirmed RAC1 production in the pancreatic islets, whole
brain, hypothalamus, heart, liver, fats, kidneys and muscles;
only the pancreatic islets showed a significant decrease in
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RAC1 production in betaRac1−/− mice (Fig. 1a). Immunos-
taining revealed that RAC1 was produced in both alpha and
beta cells in the islets of control mice, while RAC1was ablated
exclusively in pancreatic beta cells of betaRac1−/− mice
(Fig. 1b, c). Ins-Cre mice producing Cre recombinase widely
in the brain have recently been reported [21]. However, the
clone of the Ins-Cre mouse used for this study did not show
any change in expression in the hypothalamus with in situ
hybridisation [22], and no difference in blood glucose or
insulin level in intraperitoneal glucose tolerance test compared
with wild-type mouse [14]. These results indicate that
betaRac1−/− mice are indeed deficient in RAC1, specifically
in pancreatic beta cells.
BetaRac1 −/− mice showed decreased glucose-stimulated
insulin secretion Mice were reared on a normal diet; body
weight, random blood glucose levels and insulin levels
were measured in a time-course manner, but no signifi-
cant differences were found between the knockout and
control groups (Fig. 1d, e). Therefore, the mice were
reared on a high-fat diet, and their body weight, random
blood glucose levels and insulin levels were measured; no
differences were found between the two groups (Fig. 1f,
g). Next, we performed an OGTT on 8-week-old mice fed
a normal diet. In the betaRac1−/− mice, insulin levels
decreased significantly 15 min after the load, accompa-
nied by significant hyperglycaemia 15 min later (Fig. 1h,
i). In the same way, an OGTT was performed on 12-
week-old mice fed a high-fat diet, and betaRac1−/− mice
showed a decrease in insulin secretion 15 min after the
load, with significant hyperglycaemia found 15 min later
(Fig. 1j, k).
Fig. 1 Generation of betaRac1−/− mice and the effect of RAC1 abla-
tion on glucose metabolism. (a) Immunoblot analysis of RAC1 in islets
and in the brain, hypothalamus, heart, liver, fat, kidney and skeletal
muscle of control and betaRac1−/− mice. Immunostaining of pancreas
sections of control (b) and betaRac1−/− (c) mice with antibodies to
RAC1, insulin and glucagon. (d–g) Blood glucose and plasma insulin
concentrations for control (white bars) and betaRac1−/− (black bars)
mice fed normal chow (d, e) or a high-fat diet (f, g) at the age of
12 weeks. Graphs show the means ± SEM of at least ten control and
betaRac1−/− mice. (h–k) Blood glucose (h, j) and plasma insulin (i, k)
concentrations during OGTT are shown for control (n=6) and
betaRac1−/− (n=6) mice fed a normal diet (h, i) or a high-fat diet
(j, k). *p<0.05 vs the corresponding value for control mice
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No change in pancreatic beta cell mass in betaRac1−/−
mice, but insulin secretion was decreased in response to
high glucose concentrations To determine what caused this
impaired glucose tolerance, we first examined the impact of
RAC1 deficiency on islet morphology and found no signif-
icant difference between the two groups in terms of beta cell
area or pancreatic islet density (Fig. 2a–d). In addition, no
difference in insulin content was found between the two
groups (Fig. 2e). Next, to examine the insulin secretory
capacity of beta cells, we compared the amount of insulin
secreted by isolated pancreatic islets. The amount of insulin
secretion in the two groups was not significantly different
after low-glucose stimulation, whereas it was significantly
decreased in pancreatic islets isolated from the betaRac1−/−
mice after high-glucose stimulation (Fig. 2f). With KCl
stimulation, which causes depolarisation of the plasma
membrane, no differences were found between the two
groups (Fig. 2g). Moreover, the sulfonylurea agent tolbuta-
mide, which induces depolarisation by acting on ATP-
dependent K+ channels, was used for stimulation, but no
significant differences were found (Fig. 2h). These results
revealed that glucose-responsive insulin secretion is im-
paired when RAC1 is deficient in beta cells.
Insulin secretion in response to high glucose levels is also
decreased in Rac1 knockdown INS-1 cells For further con-
firmation of the results, we conducted experiments using a
system in which RAC1 was knocked down by loading
siRNA into INS-1 cells, a rat-derived beta cell line. Then,
RNA was extracted from the cells 48 h after loading the
siRNA of Rac1, and proteins were extracted 72 h after
loading. Rac1 expression was found to be significantly
decreased, both at the protein level and at the mRNA level
(Fig. 3a, b). In addition, to confirm that the knockdown
generated using siRNA was Rac1-specific, we confirmed
the expression of another isoform, ras-related C3 botulinum
toxin substrate 2 (RAC2), by using real-time PCR and found
that the knockdown has almost no impact on Rac2 expres-
sion (Fig. 3b). Rac3 could not be studied because its se-
quence in rats has not been determined. We measured
glucose-responsive insulin secretion by using RAC1 knock-
down INS-1 cells and found that high-glucose stimulation
resulted in a significant decrease in insulin secretion in the
RAC1 knockdown group (Fig. 3c), as is the case in pancre-
atic islets isolated from mice. However, high potassium
stimulation did not result in any significant difference in
insulin secretion between the two groups (Fig. 3d). These
results suggest that RAC1 contributes to insulin secretion by
responding specifically to glucose stimulation.
F-actin remains intact even in the presence of high glucose
concentrations because of RAC1 deficiency To examine the
molecular mechanism underlying the decrease in insulin
secretion because of a deficiency in RAC1, we performed
a pull-down assay using glutathione S-transferase-p21 pro-
tein (CDC42/RAC)-activated kinase (GST-PAK), the effec-
tor of RAC1, as a substrate and examined the type of insulin
secretion stimulation that activates RAC1 in INS-1 cells.
Interestingly, RAC1 was activated by stimulation with high
concentrations of glucose but not with high concentrations
of potassium (Fig. 4a). Quantitative immunoblot analysis
revealed that the level of RAC1 activation was significantly
Fig. 2 The effect of RAC1 deficiency on islet characteristics. Immu-
nostaining of pancreatic sections from control (a) and betaRac1−/− (b)
mice at the age of 16 weeks with antibodies to insulin (red) and
glucagon (green). Scale bars, 50 μm. (c) Total beta cell mass was
calculated from the area of insulin-positive cells in pancreatic sections
divided by the total area of the pancreas in 16-week-old control and
betaRac1−/− mice. (d) Islet density was determined from the number of
islets in pancreatic sections divided by the total area of the pancreas in
16-week-old control and betaRac1−/− mice. (e) Insulin content of
isolated islets at the age of 16 weeks. (f–h) Insulin release in response
to the indicated concentrations of glucose (f), KCl (g) and tolbutamide
(h) was measured in islets isolated from control (white bars) or
betaRac1−/− (black bars) mice at the age of 8 weeks. The amount of
insulin secreted from the isolated islets is normalised to insulin content.
Data were obtained from five independent experiments
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higher when stimulated with a high concentration of glucose
than when stimulated with a low concentration of glucose or
with potassium (Fig. 4a). Thus, RAC1 might be activated
only when stimulated by high glucose and might contribute
to insulin secretion.
Next, we observed the cytoskeleton of glucose-stimulated
INS-1 cells. When stimulated with low concentrations of
glucose, the F-actin in the INS-1 cells stained well, but when
stimulated with high concentrations of glucose, the amount of
stained F-actin decreased significantly. However, when RAC1
was knocked down by siRNA in INS-1 cells, significantly
reduced RAC1 production was confirmed by immunostaining
(Fig. 4f–i), and F-actin was fully stained, even during high-
glucose stimulation, indicating that the F-actin remained sig-
nificantly more intact in RAC1-deficient cells than in control
cells during high-glucose stimulation (Fig. 4b–e). For further
confirmation of the results, western blotting was performed to
quantify the polymer F-actin and the depolymerised monomer
G-actin in the glucose-stimulated INS-1 cells. Under normal
conditions, glucose stimulation causes a depolymerisation of
F-actin, and consequently the monomer G-actin increases in
quantity. However, in the INS-1 cells knocked down for
RAC1 by siRNA, the polymer F-actin was present in larger
quantities even under glucose stimulation, and no increase in
the quantity of G-actin was found (Fig. 4j). Although the
proportion of F-actin of the total actin in normal INS-1 cells
is reported not to exceed 55% [23, 24], in the present study
we found this ratio to be around 70%. This may have been
because of the 2.8 mmol/l glucose challenge, which increased
the intensity of F-actin polymerisation. Additionally, the tox-
icity of DMSO [23] and differences in the F-actin assay [24]
might have affected the proportion of F-actin. These results
suggest that glucose stimulation causes depolymerisation of
the F-actin into G-actin in INS-1 cells, but when Rac1 expres-
sion is reduced, depolymerisation is inhibited and F-actin
remains intact.
RAC1 deficiency inhibits insulin secretion by F-actin Because
the F-actin that has remained intact acts as a barrier in
RAC1-deficient cells, it was predicted that the recruitment
of insulin granules would be inhibited, causing a decrease in
insulin secretion. To examine this hypothesis, the number of
insulin granules located at the surface of the beta cell mem-
brane was counted using TIRFM, and the results revealed
that, in the beta cells of betaRac1−/−, the number of insulin
granules located at the surface of the beta cell membrane
was significantly decreased in comparison to controls
(Fig. 5a–c). This might have been because the F-actin that
remained intact in the betaRac1−/− beta cells inhibited the
recruitment of insulin granules. In addition, perfusion anal-
ysis was performed to examine, at an individual level, the
type of influence that RAC1 deficiency in pancreatic beta
cells has on the insulin secretion phase (Fig. 5d). The results
revealed that the second phase of insulin secretion was
significantly decreased in betaRac1−/− mice (Fig. 5d, e). To
confirm that the phenotypes reflected the effect of F-actin,
changes in insulin secretion were examined after the cells
were loaded with latrunculin B, a reagent that depolymerises
F-actin. Latrunculin B also promoted insulin secretion
through depolymerisation of F-actin in the beta cells of the
control group, but in the betaRac1−/− cells, a remarkable
improvement was found, and there were no differences with
the control group (Fig. 5f). The above results indicate that
insulin secretion might be reduced during glucose stimula-
tion because the F-actin of pancreatic beta cells functions as
a barrier for insulin granules in the betaRac1−/− cells.
Discussion
RAC1 is known to contribute to various disorders, including
cancer and neurological disorders [25–27]. In addition, RAC1
is associated with the translocation of GLUT4 via the non-
phosphatidylinositol 3-kinase pathway in the muscle of
patients with diabetes mellitus [28, 29]. It is also known that
many low-molecular-weight G proteins, including RAC1, in-
fluence insulin secretion in pancreatic beta cells. Although the
importance of the low-molecular-weight G protein in relation
to insulin secretion is recognised, RAC1-specific functional
analysis has never been performed in pancreatic beta cells.
Therefore, we generated betaRac1−/−mice and analysed them.
Fig. 3 Establishment of RAC1 knockdown INS-1 cells. (a, b) INS-1
cells treated with scramble siRNA (control) and Rac1 siRNA (RAC1
knockdown) were lysed and subjected to immunoblot analysis with
antibodies against RAC1 (a) or to real-time PCR analysis of Rac1 and
Rac2 mRNA (b). Relative expression values for INS-1 cells treated
with scramble siRNA (control) and are means ± SE of three indepen-
dent experiments. *p<0.05. (c, d) Insulin secretion in response to the
indicated concentrations of glucose or KCl for 30 min was assessed in
INS-1 cells and expressed as a proportion of insulin content. Data were
obtained from six independent experiments. White bars indicate con-
trol, black bars indicate RAC1 knockdown. RAC1 KD, RAC1
knockdown
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It was expected that ablation of RAC1, which mediates
cell adhesion and migration, would show morphological
abnormalities. Epithelial hyperplasia and a reduced basal
cell layer are actually found in epithelial-specific Rac1-
knockout mice [30]. However, unexpectedly, no major in-
fluence was observed in the pancreatic beta cell mass or in
pancreatic islet density in the present study, possibly be-
cause other ras-homologous (Rho)-GTPases) compensated
to form the pancreatic beta cell mass.
Although some reports have shown that RAC1 contrib-
utes to insulin secretion in the pancreatic beta cell line [7, 8],
no functional analysis of RAC1 in animals has been per-
formed. This is the first report to evaluate blood glucose
levels and serum insulin levels of the betaRac1−/− mouse. A
significant reduction in insulin secretion was found in
betaRac1−/− mice in the OGTT compared with controls.
Moreover, significantly reduced insulin secretion was ob-
served in betaRac1−/− mice when isolated islets were stim-
ulated with glucose. However, no differences in insulin
secretion between groups were observed after high KCl or
tolbutamide stimulation. Previous reports found no activated
RAC1 after high KCl stimulation and showed that when the
mutant of inactivated RAC1 was transfected into the cells,
glucose-responsive insulin secretion was inhibited without
any influence on insulin secretion after high KCl stimulation
[7]. In other words, RAC1 in pancreatic beta cells appeared
to mediate glucose-specific insulin secretion. Recently, isopre-
nylcysteine carboxyl methyltransferase (ICMT) was shown to
play an important role in glucose-induced RAC1 activation,
suggesting that ICMT is a pivotal molecule in glucose-
stimulated insulin secretion in pancreatic beta cells [31].
There are many reports that only the first phase of insulin
secretion is found after non-nutrient stimulation [32–34].
However, it was not clear which type of molecule and which
type of mechanism led to the differences in insulin secretion
after glucose stimulation. Our results suggest that the key
molecule distinguishing the second phase from the first
phase of insulin secretion might have been RAC1. Actually,
Fig. 4 Glucose-stimulated change in F-actin in RAC1-deficient INS-1
cells. (a) INS-1 cells were stimulated with the indicated concentrations of
glucose or KCl for 15 min and subjected to the measurement of GTP-
RAC1, the active form of RAC1. The bar graph shows quantification of
GTP-RAC1 levels. Data are means ± SE of four independent experi-
ments. *p<0.05, **p<0.01. (b–i) Control (b, c, f, g) and RAC1 knock-
down (d, e, h, i) INS-1 cells were starved for 30 min in a
2.8 mmol/l glucose solution and then stimulated for 15 min with
a 2.8 mmol/l or 25 mmol/l glucose solution. Staining of F-actin in
response to the indicated concentrations of glucose was assessed in INS-1
cells treated with scramble siRNA (control) and Rac1 siRNA with rho-
damine phalloidin (red) and DAPI (blue) (b–e). Immunostaining of
RAC1 in response to the indicated concentrations of glucose was assessed
in INS-1 cells treated with scramble siRNA (control) and Rac1 siRNA
with antibody to RAC1 (f–i). (j) Immunoblot analysis was performed in
2.8 mmol/l and 25 mmol/l glucose-treated INS-1 cells treated with
scramble siRNA (control) and Rac1 siRNA with antibodies to G-actin,
F-actin and total actin. The bar graph shows quantification of the G-actin
and F-actin levels. Data are means ± SE of five independent experiments.
**p<0.01. RAC1 KD, RAC1 knockdown
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we demonstrated that only the second phase of insulin
secretion was significantly reduced in betaRac1−/− mice.
Previous reports on cultured cell revealed that RAC1
controlled the second phase of insulin secretion [8],
which was demonstrated in vivo for the first time in the
present study.
In terms of factors regulating the first and second phases
of insulin secretion, previous studies have suggested that the
readily releasable pool, comprising docked insulin granules
constitutes the first phase, and the reserve pool (RP), which
is located further away, constitutes the second phase [35].
However, a recently proposed model has the second phase
of insulin secretion controlled by an RP formed out of the
actin network, irrespective of the distance from the cell
membrane or of docking onto the membrane [18]. It is
already well known that the actin cytoskeleton plays an
important role in insulin secretion [1, 36], and reports have
shown that glucose stimulates the recruitment of insulin
granules to the cell membrane through actin remodelling
[37, 38]. It was recently reported that the Rho–Rho-associ-
ated coiled-coil containing protein kinase (ROCK) signal-
ling pathway, in which Rho, another low-molecular-weight
G protein, plays an important role, regulates insulin secre-
tion via actin reorganisation in pancreatic beta cells [39]. In
our study, with high KCl stimulation and circumstances
promoting decreased Rac1 expression, no actin remodelling
occurred, suggesting that glucose-stimulated RAC1 activation
contributes to F-actin depolymerisation.
In 2007, Konstantinova et al demonstrated that EphA–
ephrin-A signalling mediates communication between adja-
cent pancreatic beta cells, thereby regulating insulin secre-
tion [2]. They showed that EphA–ephrin-A-mediated cell
communication is bidirectional, and that EphA forward
signalling inhibits insulin secretion while ephrin-A reverse
signalling stimulates insulin secretion. They also investigat-
ed the downstream targets of EphA–ephrin-A signalling and
found that the EphA forward signalling-induced decrease in
insulin secretion is accompanied by inhibition of RAC1
activity and an increase in F-actin intensity, while the
ephrin-A-reverse-signalling-induced increase in insulin se-
cretion is accompanied by enhanced RAC1 activity with
decreased F-actin intensity. However, it remains unclear
whether RAC1 activation is linked directly with F-actin
intensity, and also with insulin secretion. Here, we demon-
strated that activation of RAC1 promotes insulin secretion
via depolymerisation of F-actin, suggesting a pivotal role of
RAC1 in insulin secretion regulated by communication
between adjacent pancreatic beta cells.
Recently, synapses of amphids defective (SAD-A) kinase
was identified as a kinase that phosphorylates PAK1, an
effector of RAC1 [40]. Although evidence for molecules
that act downstream of RAC1 has been slowly accumulat-
ing, it is currently not clear how RAC1 regulates the depo-
lymerisation of F-actin. CDC42 was reported to regulate
F-actin remodelling in pancreatic beta cell lines [41, 42],
and RAC1 acts downstream of CDC42. Both RAC1 and
Fig. 5 Localisation of insulin granules in RAC1-deficient pancreatic
beta cells. (a–c) TIRFM analysis of insulin granule localisation. Com-
parison of the number of insulin granules docked to the plasma mem-
brane (shown as a highlighted ring) in pancreatic beta cells of control
(a) and betaRac1−/− (b) mice. Primary cultured pancreatic beta cells
were pre-incubated with KRBH containing 2.8 mmol/l glucose at 37°C
for 30 min, incubated with 16.8 mmol/l glucose for 15 min, fixed,
immunostained with anti-insulin antibody, and observed by TIRFM.
The surrounding lines represent the outline of a cell attached to the
cover glass. The number of docked granules was measured in a cell
surface area of 1,000 μm2. Data were obtained from three independent
experiments. (d) Glucose-stimulated insulin secretion in vivo was
assessed in control (white circles) and betaRac1−/− mice (black circles)
by perfusion analysis. (e) AUC of the first and second phases of insulin
secretion in perfusion analysis. (f) Insulin release stimulated with
16.8 mmol/l glucose was assessed with islets from control (white
bars) and betaRac1−/− mice (black bars) pre-treated with or without
10 μmol/l latrunculin B for 30 min. LatB, latrunculin B
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CDC42 regulate the second phase of insulin secretion, and
adequate ‘cycling’ of these proteins between the active state
(GTP-bound) and the inactive state (GDP-bound) is impor-
tant in insulin secretion [41, 42]. Considering that inhibition
of CDC42 cycling between GTP- and GDP-bound forms
impairs insulin secretion and F-actin regulation [41], it is
likely that the absence of RAC1 cycling resulted in inhibition
of F-actin depolymerisation in the RAC-deficient cells used in
the present study. Thus, this study provides evidence for a
crucial role of RAC1 cycling in insulin secretion via F-actin
depolymerisation in vivo.
GLP-1 secretion in L cells of the small intestine was
recently reported to be controlled by the actin barrier, sug-
gesting that low-molecular-weight G proteins such as RAC1
and CDC42 contribute to the molecular mechanism [43].
There are also reports of reduced incretin secretion being
found in patients with type 2 diabetes mellitus [44, 45], but
the secretion mechanism of incretin remains largely unclear.
Interestingly, not only insulin secretion but also incretin
secretion might be controlled by RAC1 and CDC42, but
further studies are required. Moreover, application of RAC1
to early diagnosis and treatment of diabetes mellitus war-
rants further investigation.
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